- Home
- SONN
as 05-30-2025 4:00pm EST
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 3.8M | IPO Year: | N/A |
| Target Price: | $20.00 | AVG Volume (30 days): | 35.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.08 - $16.00 | Next Earning Date: | 05-13-2025 |
| Revenue: | $1,000,000 | Revenue Growth: | 978.39% |
| Revenue Growth (this year): | 5376.22% | Revenue Growth (next year): | N/A |
Latest Sonnet BioTherapeutics Holdings Inc. News
SONN Breaking Stock News: Dive into SONN Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit
GlobeNewswire
a month ago
Sonnet Releases Virtual Investor "What This Means" Segment
GlobeNewswire
2 months ago
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
GlobeNewswire
2 months ago
Sonnet Announces Release of Corporate Update Video
GlobeNewswire
2 months ago
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.
GlobeNewswire
2 months ago
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
GlobeNewswire
2 months ago
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein
GlobeNewswire
3 months ago
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Compare SONN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SONN Sonnet BioTherapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.